Abstract
The bacterial type II fatty acid biosynthesis (FASII) pathway is an essential but unexploited target for drug discovery. In this review we summarize SAR studies on inhibitors of InhA, the enoyl-ACP reductase from the FASII pathway in M. tuberculosis. Inhibitor scaffolds that are described include the diaryl ethers, pyrrolidine carboxamides, piperazine indoleformamides, pyrazoles, arylamides, fatty acids and imidazopiperidines, all of which form ternary complexes with InhA and the NAD cofactor, as well as isoniazid and the diazaborines which covalently modify the cofactor. Analysis of the structural data has enabled the development of a common binding mode for the ternary complex inhibitors, which includes a hydrogen bond network, a large hydrophobic pocket and a third ‘size-limited’ binding area comprised of both polar and non-polar groups. A critical factor in InhA inhibition involves ordering of the substrate binding loop, located close to the active site, and a direct link is proposed between loop ordering and slow onset enzyme inhibition. Slow onset inhibitors have long residence times on the enzyme target, a property that is of critical importance for in vivo activity.
Keywords: Fabl, lnhA, enoyl-ACP reductase, drug development, drug-resistant tuberculosis, SAR studies, FASII pathway, Slow onset inhibitors, mycobacterial cell, macrophages, hydrogen bond, large hydrophobic pocket, clinical strains, mammalian cells
Current Topics in Medicinal Chemistry
Title:Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds
Volume: 12 Issue: 7
Author(s): Pan Pan and Peter J. Tonge
Affiliation:
Keywords: Fabl, lnhA, enoyl-ACP reductase, drug development, drug-resistant tuberculosis, SAR studies, FASII pathway, Slow onset inhibitors, mycobacterial cell, macrophages, hydrogen bond, large hydrophobic pocket, clinical strains, mammalian cells
Abstract: The bacterial type II fatty acid biosynthesis (FASII) pathway is an essential but unexploited target for drug discovery. In this review we summarize SAR studies on inhibitors of InhA, the enoyl-ACP reductase from the FASII pathway in M. tuberculosis. Inhibitor scaffolds that are described include the diaryl ethers, pyrrolidine carboxamides, piperazine indoleformamides, pyrazoles, arylamides, fatty acids and imidazopiperidines, all of which form ternary complexes with InhA and the NAD cofactor, as well as isoniazid and the diazaborines which covalently modify the cofactor. Analysis of the structural data has enabled the development of a common binding mode for the ternary complex inhibitors, which includes a hydrogen bond network, a large hydrophobic pocket and a third ‘size-limited’ binding area comprised of both polar and non-polar groups. A critical factor in InhA inhibition involves ordering of the substrate binding loop, located close to the active site, and a direct link is proposed between loop ordering and slow onset enzyme inhibition. Slow onset inhibitors have long residence times on the enzyme target, a property that is of critical importance for in vivo activity.
Export Options
About this article
Cite this article as:
Pan Pan and J. Tonge Peter, Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds, Current Topics in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/156802612799984535
DOI https://dx.doi.org/10.2174/156802612799984535 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamins Mediate Immunological Homeostasis and Diseases at the Surface of the Body
Endocrine, Metabolic & Immune Disorders - Drug Targets Tartrate-Resistant Acid Phosphatase: A Target for Anti-Osteoporotic Chemotherapeutics
Current Enzyme Inhibition Tuberculosis - Present Medication and Therapeutic Prospects
Current Medicinal Chemistry Accuracy of 25-Hydroxyvitamin D Assays: Confronting the Issues
Current Drug Targets Purine and Pyrimidine Pathways as Targets in Plasmodium falciparum
Current Topics in Medicinal Chemistry MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Design and In Vitro Evaluation of Five Inhibitors of Mycobacterium Tuberculosis
Letters in Drug Design & Discovery Subject Index To Volume 6
Infectious Disorders - Drug Targets Integrating the Universe of Effector and Regulatory Immune Cell Subsets: An Emerging Role of Protein-Glycan Interactions
Current Immunology Reviews (Discontinued) Prevention Interventions for People Living with HIV in Military Settings
Current HIV Research Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine Trends in Enzyme Inhibition and Activation in Drug Design - Part II
Current Topics in Medicinal Chemistry Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets
Current Drug Targets Understanding Mass Spectrometry-based Global Mycobacterial Lipidomics
Current Molecular Medicine Pharmacophore Modeling Methods in Focused Library Selection – Applications in the Context of a New Classification Scheme
Combinatorial Chemistry & High Throughput Screening Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Identification of Novel Cytotoxic T Lymphocyte Epitopes of Drug- Resistance Related Protein InhA from Mycobacterium tuberculosis
Protein & Peptide Letters Developing Country Applications of Molecular Farming: Case Studies in South Africa and Argentina
Current Pharmaceutical Design Quality-by-design Enabled Chitosan Nanoparticles for Antitubercular Therapy: Formulation, Statistical Optimization, and <i>In Vitro</i> Characterization
Current Drug Therapy An Overview of Phytotherapeutic Approaches for the Treatment of Tuberculosis
Mini-Reviews in Medicinal Chemistry